vs

Side-by-side financial comparison of Dermata Therapeutics, Inc. (DRMA) and Lottery.com Inc. (SEGG). Click either name above to swap in a different company.

Lottery.com Inc. is the larger business by last-quarter revenue ($137.7K vs $92.8K, roughly 1.5× Dermata Therapeutics, Inc.). Dermata Therapeutics, Inc. runs the higher net margin — -1853.3% vs -3226.2%, a 1372.9% gap on every dollar of revenue. On growth, Dermata Therapeutics, Inc. posted the faster year-over-year revenue change (531.8% vs -31.4%).

Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.

The Lottery Office is an Australian online lottery operator licensed by the Government of the Northern Territory and allows Australians and New Zealanders to play to win from the draws of the largest lotteries in the world, including US Powerball and Mega Millions. Its parent company, Global Players Network Pty Ltd (GPN), has been licensed and regulated to operate lotteries since 2003.

DRMA vs SEGG — Head-to-Head

Bigger by revenue
SEGG
SEGG
1.5× larger
SEGG
$137.7K
$92.8K
DRMA
Growing faster (revenue YoY)
DRMA
DRMA
+563.1% gap
DRMA
531.8%
-31.4%
SEGG
Higher net margin
DRMA
DRMA
1372.9% more per $
DRMA
-1853.3%
-3226.2%
SEGG

Income Statement — Q3 FY2023 vs Q3 FY2025

Metric
DRMA
DRMA
SEGG
SEGG
Revenue
$92.8K
$137.7K
Net Profit
$-1.7M
$-4.4M
Gross Margin
Operating Margin
-1953.3%
-3308.9%
Net Margin
-1853.3%
-3226.2%
Revenue YoY
531.8%
-31.4%
Net Profit YoY
29.1%
44.0%
EPS (diluted)
$-1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRMA
DRMA
SEGG
SEGG
Q3 25
$137.7K
Q2 25
$191.8K
Q1 25
$223.8K
Q4 24
$348.8K
Q3 24
$200.7K
Q2 24
$257.0K
Q1 24
$259.3K
Q4 23
$5.5M
Net Profit
DRMA
DRMA
SEGG
SEGG
Q3 25
$-4.4M
Q2 25
$-3.9M
Q1 25
$-3.3M
Q4 24
Q3 24
$-7.9M
Q2 24
$-5.9M
Q1 24
$-5.6M
Q4 23
$-14.7M
Gross Margin
DRMA
DRMA
SEGG
SEGG
Q3 25
Q2 25
15.1%
Q1 25
27.4%
Q4 24
69.8%
Q3 24
57.0%
Q2 24
82.3%
Q1 24
67.7%
Q4 23
-0.1%
Operating Margin
DRMA
DRMA
SEGG
SEGG
Q3 25
-3308.9%
Q2 25
-2058.5%
Q1 25
-1554.6%
Q4 24
Q3 24
-1824.1%
Q2 24
-2291.7%
Q1 24
-2157.5%
Q4 23
-271.8%
Net Margin
DRMA
DRMA
SEGG
SEGG
Q3 25
-3226.2%
Q2 25
-2022.3%
Q1 25
-1477.1%
Q4 24
Q3 24
-3954.0%
Q2 24
-2288.0%
Q1 24
-2157.3%
Q4 23
-269.8%
EPS (diluted)
DRMA
DRMA
SEGG
SEGG
Q3 25
$-1.19
Q2 25
$-0.13
Q1 25
$-0.14
Q4 24
Q3 24
$-7.86
Q2 24
$-1.12
Q1 24
$-1.40
Q4 23
$-5.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRMA
DRMA
SEGG
SEGG
Cash + ST InvestmentsLiquidity on hand
$6.6M
$320.6K
Total DebtLower is stronger
Stockholders' EquityBook value
$6.4M
$32.9M
Total Assets
$7.3M
$73.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRMA
DRMA
SEGG
SEGG
Q3 25
$320.6K
Q2 25
$262.6K
Q1 25
$468.7K
Q4 24
$68.0K
Q3 24
$60.5K
Q2 24
$28.0K
Q1 24
$84.0K
Q4 23
$359.8K
Stockholders' Equity
DRMA
DRMA
SEGG
SEGG
Q3 25
$32.9M
Q2 25
$19.8M
Q1 25
$19.9M
Q4 24
$20.5M
Q3 24
$25.7M
Q2 24
$30.7M
Q1 24
$32.5M
Q4 23
$34.5M
Total Assets
DRMA
DRMA
SEGG
SEGG
Q3 25
$73.4M
Q2 25
$53.1M
Q1 25
$53.4M
Q4 24
$52.9M
Q3 24
$58.4M
Q2 24
$62.1M
Q1 24
$63.1M
Q4 23
$64.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRMA
DRMA
SEGG
SEGG
Operating Cash FlowLast quarter
$-4.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRMA
DRMA
SEGG
SEGG
Q3 25
$-4.1M
Q2 25
$-3.2M
Q1 25
$924.9K
Q4 24
$-1.5M
Q3 24
$2.4M
Q2 24
$-368.1K
Q1 24
$-1.1M
Q4 23
$-1.3M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons